Bulletin
Investor Alert

New York Markets Open in:

Caribou Biosciences Inc.

NAS: CRBU

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jul 6, 2022, 6:39 p.m.

/zigman2/quotes/228313444/composite

$

5.80

Change

-0.0001 -0.0017%

Volume

Volume 4,604

Quotes are delayed by 20 min

/zigman2/quotes/228313444/composite

Previous close

$ 5.66

$ 5.80

Change

+0.14 +2.47%

Day low

Day high

$5.51

$5.86

Open

52 week low

52 week high

$4.89

$32.65

Open

Insider Actions for Caribou Biosciences Inc.

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/13/2022 Steven B. Kanner
Chief Scientific Officer
6,114   Derivative/Non-derivative trans. at $2.69 per share. 16,446
05/13/2022 Steven B. Kanner
Chief Scientific Officer
68,306   Derivative/Non-derivative trans. at $1.81 per share. 123,633
05/09/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/04/2022 Steven B. Kanner
Chief Scientific Officer
1,549   Derivative/Non-derivative trans. at $4.11 per share. 6,366
03/04/2022 Steven B. Kanner
Chief Scientific Officer
9,171   Derivative/Non-derivative trans. at $2.69 per share. 24,669
02/08/2022 Jason O’Byrne
Chief Financial Officer
24,336   Derivative/Non-derivative trans. at $4.11 per share. 100,020
01/26/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
01/26/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
01/25/2022 Syed Rizvi
Chief Medical Officer
60,000   Award at $0 per share. 0
01/11/2022 Ryan Fischesser
VP of Finance and Controller
6,818   Acquisition at $4.11 per share. 28,021
01/11/2022 Ryan Fischesser
VP of Finance and Controller
569   Acquisition at $2.69 per share. 1,530
12/20/2021 Ryan Fischesser
VP of Finance and Controller
1,136   Acquisition at $2.69 per share. 3,055

Transaction Summary

Total insider purchases and sales reported to the SEC

Timeframe Transactions Shares
Last 3 months
5 Purchases
0 Sales
86,694
0
Last 6 months
15 Purchases
0 Sales
211,411
0
Last 12 months
29 Purchases
1 Sales
7,017,178
3,349,395

Officers and Executives

Dr. Rachel E. Haurwitz
President, Chief Executive Officer & Director
Mr. Jason O’Byrne
Chief Financial Officer
Dr. Steven B. Kanner
Chief Scientific Officer
Ms. Cherry T. Thomas
Senior Vice President-Clinical Development
Dr. Syed Rizvi
Chief Medical Officer
Ms. Ruhi Khan
Chief Business Officer
Mr. Andrew L. Guggenhime
Director
Dr. Scott N. Braunstein
Director
Dr. Nancy C. Whiting
Director
Ms. Ran Zheng
Director
Dr. Dara Richardson-Heron
Director
Mr. David L. Johnson
Director
Dr. Natalie R. Sacks
Director
Mr. Ryan Fischesser
Vice President-Finance & Controller
Ms. Cindy Hayashi
Vice President-Human Resources
Ms. Barbara G. McClung
Secretary & Chief Legal Officer
Ms. Elaine Alambra
VP-Regulatory Affairs & Quality Assurance
Link to MarketWatch's Slice.